Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. In this interview, Andrew Kuykendall, MD, ...

Polycythemia vera is a rare condition that affects the bone marrow, which is slow to progress and typically develops in later life. It is a condition characterized by the overproduction of red blood ...

People with polycythemia vera should not skip phlebotomy appointments to manage their condition. People with blood disorders like PV may have a higher risk of blood clots if they get COVID-19. Experts ...

Besremi is a monopegylated, long-acting interferon, which exhibits its cellular effects in the bone marrow in polycythemia vera. The Food and Drug Administration (FDA) has approved Besremi ® ...

Polycythemia vera is the ultimate phenotypic consequence of the V617F mutation in Janus kinase 2 (encoded by JAK2), but the extent to which this mutation influences the behavior of the involved CD34+ ...

How Does Polycythemia Vera Advance? Polycythemia vera affects your bone marrow, the spongy tissue in the center of your bones that makes blood cells. The disease causes your bone marrow to make too ...

Between 40% to 70% of polycythemia vera patients report a history of aquagenic pruritus. 33% of these patients avoid contact with water on a daily basis, indicating severe quality-of-life restriction.

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Polycythemia vera is not hereditary. While it results from a genetic mutation, or a change in the DNA in a bone marrow cell, the change usually develops during life. It isn’t something you are born ...